Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab-based sequential first-line treatment cohorts for extensive-stage small cell lung cancer
ChiCTR2400091715Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab, etoposide, carboplatin, paclitaxel, Rivoceranib and 1 more in small cell lung cancer (SCLC) (3 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Progression-free survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
adebrelimabetoposidecarboplatinpaclitaxelRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400091715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091715.